All In Biotech

Drug Trial Radar · NCT05440851

Platform of Randomized Adaptive Clinical Trials in Critical Illness

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 6,250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

6,250

Planned (sponsor's estimate)

Start

Apr 30, 2023

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
University Health Network, TorontoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PRACTICAL is a randomized multifactorial adaptive platform trial for acute hypoxemic respiratory failure (AHRF). This platform trial will evaluate novel interventions for patients with AHRF across a range of severity states (i.e., not intubated, intubated with lower or higher respiratory system elastance, requiring extracorporeal life support) and across a range of investigational phases (i.e., preliminary mechanistic trials, full-scale clinical trials). AHRF is a common and life-threatening clinical syndrome affecting millions globally every year. Patients with AHRF are at high risk of death and long-term morbidity. Patients who require invasive mechanical ventilation are at risk of ventilator-induced lung injury and ventilator-induced diaphragm dysfunction. New treatments and treatment strategies are needed to improve outcomes for these very ill patients. Utilizing advances in Bayesian adaptive trial design, the platform will facilitate efficient yet rigorous testing of new treatments for AHRF, with a particular focus on mechanical ventilation strategies and extracorporeal life support techniques as well as pharmacological agents and new medical devices. The platform is designed to enable evaluation of novel interventions at a variety of stages of investigation, including pilot and feasibility trials, trials focused on mechanistic surrogate endpoints for preliminary clinical evaluation, and full-scale clinical trials assessing the impact of interventions on patient-centered outcomes. A domain is defined as a set of interventions that are intended to act on specific mechanisms of injury using different variations of a common therapeutic strategy. A domain may also be a non-interventional study that addresses observational research questions by collecting specific data or outcomes that are not collected as part of other domains. Domains are intended to function independently of each other, allowing independent evaluation of multiple therapies and mechanistic pathways within the same patient. Once feasibility is established, Bayesian adaptive statistical modelling will be used to evaluate treatment efficacy at regular interim adaptive analyses of the pre-specified outcomes for each intervention in each domain. These adaptive analyses will compute the posterior probabilities of superiority, futility, inferiority, or equivalence for pre-specified comparisons within domains. Each of these potential conclusions will be pre-defined prior to commencing the intervention trial. Decisions about trial results (e.g., concluding superiority or equivalence) will be based on pre-specified threshold values for posterior probability. The primary outcome of interest, the definitions for superiority, futility, etc. (i.e., the magnitude of treatment effect) and the threshold values of posterior probability required to reach conclusions for superiority, futility etc., will vary from intervention to intervention depending on the phase of investigation and the nature of the intervention being evaluated. All of these parameters will be pre-specified as part of the statistical design for each intervention trial. In general, domains will be designed to evaluate treatment effect within four discrete clinical states: non-intubated patients, intubated patients with low respiratory system elastance (\<2.5 cm H2O/(mL/kg)), intubated patients with high respiratory system elastance (≥2.5 cm H2O/(mL/kg)), and patients requiring extracorporeal life support. Where appropriate, the model will specify dynamic borrowing between states to maximize statistical information available for trial conclusions. In this perpetual trial design, different interventions may be added or dropped over time. Where possible, the platform will be embedded within existing data collection repositories to enable greater efficiency in outcome ascertainment. Standardized systems for acquiring both physiological and biological measurements are embedded in the platform, to be acquired at sites with appropriate training, expertise, and facilities to collect those measurements.

Conditions

  • Respiratory Insufficiency
  • Extracorporeal Membrane Oxygenation Complication
  • Mechanical Ventilation Pressure High

Interventions

  • Ultra-Protective Ventilation Facilitated by Extracorporeal SupportOther

    Patients randomized to this intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.

  • Lung-Protective Ventilation (LPV)Other

    Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.

  • Driving Pressure-Limited Ventilation (DPL)Other

    Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.

  • Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS)Other

    Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.

  • Early Cohort corticosteroid doseDrug

    Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.

  • Extended Cohort corticosteroid doseDrug

    Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).

  • Usual care without routine corticosteroidsDrug

    Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.

  • Usual care without extending corticosteroidsDrug

    Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.

  • Usual care with fludrocortisoneDrug

    Best practice standard of care prescribed by treating team + fludrocortisone 50μg enterally daily for 7 days.

  • Usual care without fludrocortisoneDrug

    Best practice standard of care prescribed by treating team without fludrocortisone. After randomization, if a clinical indication develops for fludrocortisone as part of standard of care, administration of fludrocortisone is not prohibited. Any fludrocortisone administered to participants in the control arm will be documented.

  • Drug 4 mL:Drug

    4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.

  • Drug 40 mg:Drug

    40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours

  • PEEP-20Other

    fixed high positive end-expiratory pressure at 20 cmH2O

  • PEEP-AOPOther

    positive end-expiratory pressure set according to airway opening pressure

  • PEEP-10Other

    fixed lower positive end-expiratory pressure at 10 cmH2O

  • VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitationOther

    Patients randomized to this intervention group will receive VV-ECMO where the sedation will be reduced and the ventilator will will be adjusted to facilitate spontaneous breathing.

  • Electrical impedance tomography (EIT)Other

    Patients randomized to EIT will have PEEP titration compared via the Overdistension Collapse Intercept (ODCL) versus that obtained using a standard high PEEP table.

  • no treatment / intervention arm is involvedOther

    This trial is a prospective, multicenter, observational study (no treatment arm is involved).

  • Usual careOther

    Patients will be treated according to usual care.

  • Early Routine IMTOther

    * Training commences once patients meet readiness to wean criteria * 3 sets of 10 breaths, delivered twice daily using a device placed at the airway opening to apply an external resistive pressure load, until hospital discharge, death, or day 45 after randomization, whichever occurs first. * Device load will initially be set to 30% of the MIP. * Device load will be titrated upward (in increments of 5-10% of MIP, to a maximum of 60% of MIP) as needed to achieve a modified Borg dyspnea score of 7/10 or visible accessory muscle use.

  • no treatment / intervention arm is involved.Other

    This trial is a prospective, multicenter, observational study (no treatment arm is involved).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EXPAND-ECLS domain - determine the feasibility of recruiting 100 patients over 2 years of active enrolment, as well as assess the rate of participant recruitment and understand the barriers to enrollment.Time frame: 2 years of active site enrollment.
  2. FLUDRO-1 and IMV domains - ventilator-free days to day 28 in DPL vs LPV (DRIVE RCT)Time frame: Day 28 post randomization
  3. IMV domain - adherence to LDPVS management (LANDMARK RCT)Time frame: Day 28
  4. IMV domain - probability of achieving and maintaining lung- and diaphragm-protective targets during mechanical ventilation (LANDMARK RCT)Time frame: Day 28
  5. IMV domain - protocol adherence (EIT intervention)Time frame: Day 9
  6. CORT-E2 domain - 60-day mortality from the day of randomizationTime frame: Day 60
  7. FLUDRO-1 domain - Successful enrollment of participantsTime frame: 18-month enrolment period across three platform trials (PRACTICAL, REMAP-CAP and ATTACC-CAP)
  8. FAST-3 domain - Advanced respiratory support free daysTime frame: Day 28
  9. IMV-ECLS domain - feasibility of enrollment and protocol adherenceTime frame: For feasibility of enrollment: 2 years of active site enrollment; For protocol adherence, these will be evaluated at 7 days (once the intervention period ends)
  10. ESCAPE domain - 28-day all-cause mortalityTime frame: 28-day
  11. IMPROV domain - recruitment rate, protocol adherence, and vital statusTime frame: Throughout trial enrollment for recruitment rate and protocol adherence, and up to day 90 for vital status.
  12. WAVEFORM domainTime frame: considering death as a competing event

Locations

103 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona · Recruiting

  • University of California Los Angeles (UCLA)

    Los Angeles, California · Recruiting

  • University of San Diego (UCSD)

    San Diego, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • University of Kentucky

    Lexington, Kentucky · Recruiting

  • University of Maryland Medical System

    Baltimore, Maryland · Recruiting

  • The Johns Hopkins Medicine

    Baltimore, Maryland · Recruiting

  • VA Ann Arbor Healthcare System

    Ann Arbor, Michigan · Recruiting

  • University of Michigan Health

    Ann Arbor, Michigan · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Mount Sinai New York City

    New York, New York · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina · Recruiting

  • University of Cincinnati College of Medicine

    Cincinnati, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Oregon Health & Science University (OHSU)

    Portland, Oregon · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, Pennsylvania · Recruiting

  • Rhode Island Hospital

    Providence, Rhode Island · Recruiting

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina · Recruiting

  • Vanderbilt university medical center

    Nashville, Tennessee · Recruiting

  • Texas Tech

    El Paso, Texas · Recruiting

  • University of Utah Health

    Farmington, Utah · Recruiting

  • Sentara Health

    Norfolk, Virginia · Recruiting

  • Westmead Hospital

    Westmead, Australia · Recruiting

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia · Recruiting

  • Nepean Hospital

    Kingswood, New South Wales, Australia · Recruiting

  • Wollongong Hospital

    Wollongong, New South Wales, Australia · Recruiting

  • The Prince Charles Hospital

    Chermside, Queensland, Australia · Recruiting

  • Flinders Medical Centre

    Bedford Park, Southern Adelaide, Australia · Recruiting

  • St Vincent Hospital, Sydney

    Darlinghurst, Sydney, Australia · Recruiting

  • Bendigo Health Victoria

    Bendigo, Victoria, Australia · Recruiting

  • Peninsula University Hospital

    Frankston, Victoria, Australia · Recruiting

  • University Hospital Geelong

    Geelong, Victoria, Australia · Recruiting

  • The Austin Hospital

    Heidelberg, Victoria, Australia · Recruiting

  • University of Calgary

    Calgary, Alberta, Canada · Recruiting

  • University of Alberta/Edmonton University Hospital

    Edmonton, Alberta, Canada · Recruiting

Showing 40 of 103 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.